Chart-Typ:
Zeitraum:
| JNJ: TREMFYA Phase 3b Study Meets Key Endpoints In Adults With Active Psoriatic Arthritis | NEW BRUNSWICK (dpa-AFX) - Drug major Johnson & Johnson (JNJ) announced Friday positive results from the TREMFYA (guselkumab) Phase 3b APEX study in adults living with active psoriatic arthritis... ► Artikel lesen |
| Johnson & Johnson scheitert mit einem Texas-Two-Step-Verfahren, über das auch bei Bayer zur Beilegung von Glyphosat-Streitigkeiten nachgedacht wird | Etliche Rechtsstreitigkeiten rund um Glyphosat sorgen noch immer für Verunsicherung unter den Anteilseignern von Bayer. Zehntausende Verfahren sind aktuell noch anhängig und erst kürzlich wurde das... ► Artikel lesen |
| Johnson & Johnson Set To Complete Acquisition Of Intra-Cellular Therapies By April 2, 2025 | NEW BRUNSWICK (dpa-AFX) - Johnson & Johnson (JNJ) announced that following the approval of its pending acquisition of Intra-Cellular Therapies by Intra-Cellular Therapies' shareholders on March... ► Artikel lesen |
| Biogen Says FDA Grants Fast Track Designation To BIIB080 For Treatment Of Alzheimers Disease | WESTON (dpa-AFX) - Biogen Inc. (BIIB) announced Wednesday that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to BIIB080, an investigational antisense oligonucleotide... ► Artikel lesen |
| Biogen Inc.: Biogen's Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer's Disease | CAMBRIDGE, Mass., April 02, 2025Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BIIB080, an investigational antisense oligonucleotide... ► Artikel lesen |
| Biogen Plans For State-of-the-Art Global Headquarters At Kendall Common, Set To Open In 2028 | WESTON (dpa-AFX) - Biogen Inc. (BIIB) announced Monday plans for its new global headquarters at Kendall Common, located at 75 Broadway in Cambridge, as part of a multi-year real estate consolidation... ► Artikel lesen |
| BioCryst Pharmaceuticals, Inc.: BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | RESEARCH TRIANGLE PARK, N.C., April 04, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted... ► Artikel lesen |
| BioCryst Pharmaceuticals, Inc.: BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | RESEARCH TRIANGLE PARK, N.C., March 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted... ► Artikel lesen |
| BioCryst Pharmaceuticals, Inc.: BioCryst Reports Fourth Quarter and Full Year 2024 Financial Results and Upcoming Key Milestones | -ORLADEYO net revenue of $124.2 million for Q4 2024 (+36.6 percent y-o-y) and $437.7 million for FY 2024 (+34.3 percent y-o-y)- -FY 2025 ORLADEYO net revenue guidance increased to between $535-$550... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BG MEDICINE INC finden Sie auf Wallstreet Online.
